NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Mitox
|
Novantron
|
Novantrone
|
|
|
Synonyms
|
DHAD
|
DHAQ
|
DHAQ HCl
|
Dihydroxyanthraquinone
|
Mitoxanthrone
|
Mitoxantron
|
Mitoxantrona [INN-Spanish]
|
Mitoxantrone 2HCl
|
Mitoxantrone dihydrochloride
|
Mitoxantrone HCl
|
Mitoxantrone hydrochloride
|
Mitoxantronum [INN-Latin]
|
Mitozantrone hydrochloride
|
Mitozantrone
|
mitoxantrone
|
Mitoxantrone
|
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione Hydrochloride
|
Bisantrone
|
CL 232315
|
Immunex
|
NCI 301739
|
NSC 301739
|
Novatrone
|
Mitoxantrone Dihydrochloride
|
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
|
1,4-Bis[(2-(2-hydroxyethylamino)ethyl)amino]-5,8-dihydroxyanthraquinone
|
Mitox
|
Nimitoxantron
|
Novantron
|
Novantrone
|
Ralenova
|
NSC 279836
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
9.775683
|
H Acceptors
|
10
|
H Donor
|
8
|
LogD (pH = 5.5)
|
-4.25051
|
LogD (pH = 7.4)
|
-1.2001225
|
Log P
|
1.1855145
|
Molar Refractivity
|
123.5338 cm3
|
Polarizability
|
45.86351 Å3
|
Polar Surface Area
|
163.18 Å2
|
Rotatable Bonds
|
12
|
Lipinski's Rule of Five
|
false
|
Log P
|
0.91
|
LOG S
|
-2.78
|
Solubility (Water)
|
7.34e-01 g/l
|
DETAILS
DETAILS
DrugBank
Selleck Chemicals
TRC
DrugBank -
DB01204
|
Item |
Information |
Drug Groups
|
approved; investigational |
Description
|
An anthracenedione-derived antineoplastic agent. [PubChem] |
Indication |
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis |
Pharmacology |
Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. |
Toxicity |
Severe leukopenia with infection. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic |
Absorption |
Poorly absorbed following oral administration |
Half Life |
75 hours |
Protein Binding |
78% |
Distribution |
* 1000 L/m2 |
Clearance |
* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2] * 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2] * 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2] |
References |
• |
Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74.
[Pubmed]
|
|
External Links |
|
|
Selleck Chemicals -
S2485
|
Research Area: Cancer Biological Activity: Mitoxantrone Hydrochloride (NSC301739; Immunex) is a hydrochloride salt of mitoxantrone which is a synthetic antineoplastic anthracenedione (IC50 = 0.42 mM).Mitoxantrone Hydrochloride (NSC301739; Immunex) is also a synthetic antineoplastic anthracenedione. Mitoxantrone Hydrochloride (NSC301739; Immunex) is a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone Hydrochloride (NSC301739; Immunex) also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. Mitoxantrone Hydrochloride (NSC301739; Immunex) has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. [1][2] |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. Pubmed
- • Parker C et al. Lancet. 2010 Dec 11;376(9757)
- • McDonald, M., et al.: Drugs Exp. Clin. Res., 10, 745 (1984)
- • Beijnen, J.H., et al.: Anal. Profiles Drug Subs., 17, 221 (1984)
- • McDonald, M., et al.: Drugs Exp. Clin. Res., 10, 745 (1984)
- • Beijnen, J.H., et al.: Anal. Profiles Drug Subs., 17, 221 (1984)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent